Abstract
Yellow fever vaccine is a live, attenuated viral preparation from the 17D virus strain. Since 1996, 34 cases of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) have been described. We report a new case of YEL-AVD. Given the potential risks associated with the vaccine, physicians should consider vaccination only for patients truly at risk for exposure to yellow fever, especially for primovaccination.
MeSH terms
-
Adult
-
Female
-
Humans
-
Male
-
Middle Aged
-
Multiple Organ Failure / etiology*
-
Multiple Organ Failure / immunology
-
Multiple Organ Failure / therapy
-
Respiratory Distress Syndrome / etiology
-
Risk Factors
-
Spain
-
Systemic Inflammatory Response Syndrome / etiology
-
Treatment Outcome
-
Vaccines, Attenuated / adverse effects
-
Yellow Fever / immunology
-
Yellow Fever / prevention & control*
-
Yellow Fever Vaccine / administration & dosage
-
Yellow Fever Vaccine / adverse effects*
Substances
-
Vaccines, Attenuated
-
Yellow Fever Vaccine